Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study-Reference-Cited by-同舟云学术

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Published:2019-09 Issue:9 Volume:20 Page:1239-1251
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Robert Caroline,Ribas Antoni,Schachter Jacob,Arance Ana,Grob Jean-Jacques,Mortier Laurent,Daud Adil,Carlino Matteo S,McNeil Catriona M,Lotem Michal,Larkin James M G,Lorigan Paul,Neyns Bart,Blank Christian U,Petrella Teresa M,Hamid Omid,Su Shu-Chih,Krepler Clemens,Ibrahim Nageatte,Long Georgina V

Funder

Merck

Meso Scale Diagnostics

Roche

Merck Sharp and Dohme

Les Laboratories Pierre Fabre

British Microcirculation Society

Amgen

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

3. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial;Ascierto;JAMA Oncol,2018

4. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial;Larkin;J Clin Oncol,2018

5. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma;Ribas;JAMA,2016

Cited by 863 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis;Computational and Structural Biotechnology Journal;2024-12

2. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

3. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

4. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

5. Early versus late response to PD-1-based immunotherapy in metastatic melanoma;European Journal of Cancer;2024-10